Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent company, Elixirgen, LLC, which has been in active operation since the beginning of 2012.